Ochre Bio
Ochre Bio is a UK-based biotechnology company focused on developing RNA therapies for chronic liver diseases. They leverage a proprietary platform that combines human genomic and phenotypic data with advanced computational and multi-omic technologies to identify and validate therapeutic targets. Their approach involves deep phenotyping of human liver samples and models, followed by validation in sophisticated human systems, including cell co-cultures and perfused whole human livers. Ochre Bio's RNA chemistry platform enables rapid progression of targets to validated leads, aiming to address significant unmet needs in liver health. The company has established partnerships with major pharmaceutical companies such as GSK, Boehringer Ingelheim, and Takeda, indicating strong industry validation and traction. Their scientific team comprises experts in genomics, machine learning, and drug discovery.
Ochre Bio
Ochre Bio is a UK-based biotechnology company focused on developing RNA therapies for chronic liver diseases. They leverage a proprietary platform that combines human genomic and phenotypic data with advanced computational and multi-omic technologies to identify and validate therapeutic targets. Their approach involves deep phenotyping of human liver samples and models, followed by validation in sophisticated human systems, including cell co-cultures and perfused whole human livers. Ochre Bio's RNA chemistry platform enables rapid progression of targets to validated leads, aiming to address significant unmet needs in liver health. The company has established partnerships with major pharmaceutical companies such as GSK, Boehringer Ingelheim, and Takeda, indicating strong industry validation and traction. Their scientific team comprises experts in genomics, machine learning, and drug discovery.